Literature DB >> 10569314

QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.

F F Samaha.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569314     DOI: 10.1016/s0002-9343(99)00171-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  11 in total

1.  Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.

Authors:  P B Iannini; S Doddamani; E Byazrova; I Curciumaru; H Kramer
Journal:  BMJ       Date:  2001-01-06

Review 2.  Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.

Authors:  Galia Jackobson; Narin Nard Carmel; Dor Lotan; Anjelika Kremer; Dan Justo
Journal:  Z Gerontol Geriatr       Date:  2016-11-22       Impact factor: 1.281

Review 3.  [Ventricular tachyarrhythmia as a side effect of pharmacotherapy].

Authors:  Thomas Demming; Hendrik Bonnemeier
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-05-09

Review 4.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.

Authors:  S J Martin; R Jung; C G Garvin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 6.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Authors:  Gerrit Frommeyer; Lars Eckardt
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

7.  Safety of fluoroquinolones: An update.

Authors:  L Mandell; G Tillotson
Journal:  Can J Infect Dis       Date:  2002-01

Review 8.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Levofloxacin: an updated review of its use in the treatment of bacterial infections.

Authors:  Miriam Hurst; Harriet M Lamb; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review.

Authors:  Peter Ball
Journal:  Curr Ther Res Clin Exp       Date:  2003-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.